Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Soluble thrombomodulin levels in plasma of multiple sclerosis patients and their implication.
Teriflunomide, an immunomodulatory drug, exerts anticancer activity in triple negative breast cancer cells.
Enzon presents pre-clinical data on controlled release of PEGylated interferon-beta-1b and PEGylated anti-TNF-a antibody fragment at the Controlled Release Society annual meeting
Santhera Announces Successful Outcome of Phase III Study with Catena®/Raxone® in Duchenne Muscular Dystrophy
Untargeted plasma metabolomics identifies endogenous metabolite with drug-like properties in chronic animal model of multiple sclerosis.
Physicians from Accentia and Johns Hopkins University present plans for new MS drug study for Cyrevia
Impact of sleep disorder treatment on fatigue in multiple sclerosis.
The effect of low-dose naltrexone on quality of life of patients with multiple sclerosis: a randomized placebo-controlled trial.
Receptos announces issuance of composition of matter patents covering proprietary lead product candidate RPC1063
Monomethyl fumarate promotes Nrf2-dependent neuroprotection in retinal ischemia-reperfusion.
Altered Expression of Oligodendrocyte and Neuronal Marker Genes Predicts the Clinical Onset of Autoimmune Encephalomyelitis and Indicates the Effectiveness of Multiple Sclerosis-Directed Therapeutics.
The Clinical Meaning of Walking Speed as Measured by the Timed 25-Foot Walk in Patients With Multiple Sclerosis.
Biogen Idec's PLEGRIDY™ (peginterferon beta-1a) approved in the US for the treatment of multiple sclerosis
RILUTEK®
Vitamin D and multiple sclerosis: epidemiology, immunology, and genetics.
Genmab announces positive top-line Phase II results of ofatumumab in multiple sclerosis
Increased Serum Brain-derived Neurotrophic Factor in Multiple Sclerosis Patients on Interferon-β and Its Impact on Functional Abilities.
lambda-Interferons and the single nucleotide polymorphisms: A milestone to tailor-made therapy for chronic hepatitis C.
Elevation of Sema4A Implicates Th Cell Skewing and the Efficacy of IFN-β Therapy in Multiple Sclerosis.
Clinical relevance of differential lymphocyte recovery after alemtuzumab therapy for multiple sclerosis.
Takeda Pharmaceutical: New Drug Application Approval in Japan for Copaxone® Subcutaneous Injection 20 mg Syringe, a Drug for the Treatment of Multiple Sclerosis
Neuropathology of white matter disease in Leber's hereditary optic neuropathy.
Gene expression studies of a human monocyte cell line identify dissimilarities between differently manufactured glatiramoids.
Glatiramer acetate fights against Alzheimer's disease by inducing dendritic-like microglia expressing insulin-like growth factor 1.
Prospective Observational Long-term Safety Registry of Multiple Sclerosis Patients Who Have Participated in Cladribine Clinical Trials

Pages